Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection
Mario A. Martínez, Ting-Yi Chen, Hosoon Choi, Munok Hwang, Dhammika H. Navarathna, Linhue Hao, Michael Gale, Grégory Camus, Hector E Ramirez, Chetan Jinadatha
Abstract
Persistent severe acute respiratory syndrome coronavirus 2 infection is difficult to treat. Here, we report a case of 5-month persistent coronavirus disease 2019 in an immunocompromised patient who was successfully treated with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution to cure these patients with difficult-to-treat infections.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDiseaseIntensive care medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchDrug-Induced Adverse Reactions